Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 222 of 6351
-
Can a targeted cancer drug deliver in the real world?
Disease control Recruiting nowTrastuzumab deruxtecan's (T-DXd's) efficacy and safety has been confirmed in traditional clinical trials, there is a lack of real-world evidence, especially among Chinese patients. The objective of this study is to evaluate real-world effectiveness and safety profile of T-DXd by …
Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a drug duo outsmart returning lymphoma?
Disease control Recruiting nowAn open-label, single-arm, single-center, phase II clinical trial to evaluate the feasibility, efficacy and safety of Glofitamab Combination with chidamide in patients with recurrent/refractory diffuse large B-cell lymphoma.
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265 (225Ac-PSMA-I\&T) in combination with Olaparib in participants with mCRPC. The dose optimization Phase 2 part will be investigating the safety, tolerability, a…
Phase 2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Promising drug cocktail takes on tough lymphoma
Disease control Recruiting nowThis open-label, multicenter, three cohorts, phase II study is designed to assess a combination of Zanubrutinib/Venetoclax/Glofitamab or Venetoclax/Glofitamab in high-risk subjects with either first line or R/R Mantle Cell Lymphoma (MCL). Three independent cohorts will be run: …
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Immune cell therapy takes on tough autoimmune diseases
Disease control Recruiting nowA Clinical Study Exploring CT1190B in the treatment of patients with moderate to severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc)
Phase 1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental CAR T-Cell therapy takes on tough lymphoma
Disease control Recruiting nowThis is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Phase 2 • Sponsor: March Biosciences Inc • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Engineered immune cells take on tough lymphoma in new trial
Disease control Recruiting nowThis is a Prospective Single Center, open label, Non-randomized, Single Arm, Single Dose, Phase II Clinical Trial. Adult patients \>18-year-old with CD19+ Non-Hodgkin lymphoma are eligible for the study if they meet eligibility criteria. Patients will receive a fresh single dose …
Phase 2 • Sponsor: King Hussein Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Can a placental patch help heal stubborn diabetic foot ulcers?
Disease control Recruiting nowA multi-center, prospective, observer-blinded, randomized controlled clinical trial to evaluate the efficacy of PPECM augmented standard of care versus standard of care alone in the management of hard-to-heal diabetic foot ulcers.
Sponsor: ConvaTec Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a catheter device clear lung clots and ease heart strain?
Disease control CancelledThis study is a prospective, single-arm, non-randomized, interventional, multicenter feasibility study to evaluate the safety and effectiveness of percutaneous mechanical thrombectomy using the Akura Thrombectomy System in subjects with acute pulmonary embolism (PE).
Sponsor: Akura Medical • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug cocktail aims to stop lung cancer relapse in High-Risk patients
Disease control Recruiting nowOpen-label, phase III, randomized, stratified (PDL1- vs PDL1+), 3 arms, multicenter clinical trial. 129 resected patients (43 per arm) with stage from IB to IIIA and IIIB (N2) non-small cell lung cancer that do not achieve pathologic complete response (pCR) after neoadjuvant tre…
Phase 3 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Can a Two-Pill combo tame stubborn high cholesterol?
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia
Phase 3 • Sponsor: Addpharma Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can targeted brain zaps quiet the voices in schizophrenia?
Symptom relief Recruiting nowThe purpose of the study is to test the hypothesis that functionally navigated repetitive TMS stimulations to the prefrontal cortex (PFC) modulate aberrant cortical electrical activities at PFC circuitry. The TMS location of the PFC site will be individually localized by the symp…
Sponsor: The University of Texas Health Science Center, Houston • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Could a stem cell boost keep T-Cell lymphoma away longer?
Disease control Recruiting nowThis phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. Usual treatment after a complete response …
Phase 3 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New vaccine aims to shield infants from 25 strains of pneumonia
Vaccine OngoingPhase 2 trial to evaluate safety and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in Healthy Infants
Phase 2 • Sponsor: Inventprise Inc. • Aim: Vaccine
Last updated Jun 26, 2026 12:34 UTC
-
Could a simple blood test let some breast cancer patients stop treatment?
Disease control Recruiting nowHeroes is a multicentre, national, non-randomized, open-label, phase 2 study. The goal of this clinical trial is to evaluate the feasibility of therapeutic de-escalation in HER2-positive metastatic breast cancer with disease controlled after 2 years of maintenance treatment with …
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could a sleep hormone stop Children's Post-Surgery delirium?
Prevention Recruiting nowPostoperative agitation and emergence delirium describe a spectrum of symptoms of early postoperative negative behavior, in which the child experiences a variety of behavioral disturbances including crying, thrashing, and disorientation during early awakening from anaesthesia. Th…
Phase 3 • Sponsor: Arash Afshari • Aim: Prevention
Last updated Aug 20, 2026 00:00 UTC
-
New combo therapy aims to tame chronic GVHD
Disease control Recruiting nowThis study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug cocktail aims to wipe out bladder tumors before surgery
Disease control OngoingThe main objective of this trial is to evaluate the efficacy of the combo Sacituzumab govitecan (SG) + Zimberelimab (AB 122) (ZIM) + Domvanalimab (AB 154) (DOM), measured as pathologic complete response (pCR) rates, in the perioperative setting in patients with Muscle Invasive Bl…
Phase 2 • Sponsor: Fundación para el Progreso de la Oncología en Cantabria • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Can Lab-Made antibodies give HIV patients a break from daily pills?
Disease control OngoingFor people living with HIV, antiretroviral therapy (ART) helps to stop the virus from multiplying. The goal of current HIV treatment is to have such a small amount of the virus in the blood that it does not show up on regular tests. HIV is also hidden in cells throughout the body…
Phase 2 • Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Could cow tissue make breast reconstruction safer?
Disease control OngoingIn 2020, more than 31,000 new cancer cases were reported in Kazakhstan, with breast cancer being the most common type, accounting for more than 4,200 new cases. This pattern has also been observed in previous years, making breast cancer a major public health concern in the countr…
Sponsor: National Research Oncology and Transplantology Center, Kazakhstan • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC